

RX Herculink Elite

Renal Stent System

Outstanding product performance

Low restenosis

Sustained hypertension reduction

Excellent technical performance Outstanding clinical efficacy









From Design to Outcomes

Building on the outstanding deliverability of RX Herculink, RX Herculink Elite sets standards in renal stenting with its advanced cobalt chromium metallurgy, providing thin, strong strut thickness with high radial strength, superb stent flexibility, excellent scaffolding and radiopacity.

The **HERCULES** Study met its primary endpoint and showed significant blood pressure reduction at 9 months.


This result comes without compromising safety.

Outstanding Product Performance

Cobalt Chromium Technology

Remarkably thin struts, with outstanding radial strength and visibility.






Designed for Delivery and Conformability

Flexible system designed to navigate and conform to challenging take-offs.



Based on Leading MULTI-LINK Platform

Excellent acute performance and scaffolding.



Low Restenosis

Primary Endpoint

- 9-month binary restenosis 10.5% (p<0.0001) n=202 patients/241 lesions²
 - Significantly lower than the performance goal of 28.6%²


Key Safety Endpoint

- **98.5%** Freedom from death, ipsilateral nephrectomy and embolic events resulting in kidney damage through 30 days²
- 96.9% Freedom from clinically driven TLR through 270 days²

Sustained Hypertension Reduction

Reduced Systolic Blood Pressure

• 77.5% of patients had a persistent reduction in systolic pressure at 9 months (n=173) (p<0.0001)²



RX Herculink Elite

Peripheral Stent System

Orde	ing In	formatio	n						
Catheter length (cm)	Stent diameter (mm)	Stock number (Include stent length extension) Catheter length	Suffix stent length (mm)	Maximum post dilatation diameter (mm)	Rated burst pressure (atm)	Shaft diameter proximal/distal (F/F)	Maximum crimped stent OD (mm)	Minimum sheath size (F)	Minimum guiding catheter ID (F/mm)
80 cm	4.0	1011521	-12, -15, -18	7.0	14	3.3F / 2.9F	1.70	5F	6F / 1.70
	4.5	1011524	-12, -15, -18	7.0	14	3.3F / 2.9F	1.70	5F	6F / 1.70
	5.0	1011527	-12, -15, -18	7.0	14	3.3F / 2.9F	1.70	5F	6F / 1.70
	5.5	1011530	-12, -15, -18	7.0	14	3.3F / 3.3F	1.70	5F	6F / 1.70
	6.0	1011533	-12, -15, -18	7.0	14	3.6F / 3.3F	1.70	5F	6F / 1.70
	6.5	1011536	-12, -15, -18	8.0	14	3.6F / 3.5F	1.70	5F	6F / 1.70
	7.0	1011539	-15, -18	8.0	14	3.6F / 3.5F	1.70	5F	6F / 1.70
135 cm	4.0	1011522	-12, -15, -18	7.0	14	3.3F / 2.9F	1.70	5F	6F / 1.70
	4.5	1011525	-12, -15, -18	7.0	14	3.3F / 2.9F	1.70	5F	6F / 1.70
	5.0	1011528	-12, -15, -18	7.0	14	3.3F / 2.9F	1.70	5F	6F / 1.70
	5.5	1011531	-12, -15, -18	7.0	14	3.3F / 3.3F	1.70	5F	6F / 1.70
	6.0	1011534	-12, -15, -18	7.0	14	3.6F / 3.3F	1.70	5F	6F / 1.70
	6.5	1011537	-12, -15, -18	8.0	14	3.6F / 3.5F	1.70	5F	6F / 1.70
	7.0	1011540	-15, -18	8.0	14	3.6F / 3.5F	1.70	5F	6F / 1.70

Interna	tional (CE) St	ent Co	mplian	ce Lab	eling		
Pressure (atm)								
(attri)	4.0	4.5	5.0	5.5	6.0	6.5	7.0	
11	4.00	4.50	5.00	5.50	6.00	6.50	7.00	NOMINAL
12	4.08	4.60	5.13	5.61	6.13	6.61	7.14	
13	4.15	4.68	5.25	5.72	6.25	6.71	7.27	
14	4.21	4.77	5.35	5.82	6.36	6.81	7.39	RATED BURST PRESS
15	4.28	4.84	5.46	5.91	6.47	6.90	7.50	
16	4.33	4.91	5.55	5.99	6.56	6.98	7.61	
17	4.39	4.98	5.64	6.07	6.66	7.06	7.70	

References: 1. Kastrati et al. Circulation 2001 June 12;103(23):2816-21. **2.** Presented by Michael R. Jaff, D.O., Does Elevated Brain Natriuretic Peptide (BNP) Predict Outcomes for Patients with Uncontrolled Hypertension in Renal Artery Stenting? Results from the HERCULES Study. SCAI 2011.

HERCULES is an Abbott Vascular Sponsored Study – All Abbott Vascular products in this study are used in accordance with approved IFU and regulatory requirements. Abbott does not promote out of intended use for its products.

RX Herculink Elite and MULTI-LINK are trademarks of the Abbott Group of Companies.

Palmaz Blue is a trademark of Cordis. Express SD is a trademark of Boston Scientific Corporation or its affiliates. Racer RX is a trademark of Medtronic.

Contact your local representative for more information

Abbott Vascular International BVBA. Park Lane, Culliganlaan 2B, B-1831 Diegem, Belgium, Tel: +32 2 714 14 11

Photo(s) on file at Abbott Vascular. All drawings are artist's representations only and should not be considered as an engineering drawing or photograph. Products intended for use by or under the direction of a physician. Prior to use, it is important to read the package insert thoroughly for instructions for use, warnings and potential complications associated with use of this device. Information contained herein is for distribution for Europe, Middle East and Africa ONLY. Please check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.

For more information, visit our website at abbottvascular.com

© 2013 Abbott. All rights reserved. 2-EH-1-1638-01 09-2013 REV A

